Fusidic Acid
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Fusidic Acid: From Staphylococcal Infections to Exposure Keratitis
One-Sentence Summary
Fusidic acid is a fusidane-class antibiotic historically used against Staphylococcus aureus infections, though this evidence pack does not record a specific approved indication or product license for it. The TxGNN model’s top-ranked prediction is that fusidic acid may be effective for Exposure Keratitis, but this direction is currently supported by 0 clinical trials and only 1 publication, and that publication does not directly involve fusidic acid or exposure keratitis — the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (Fusidic acid is a known antistaphylococcal antibiotic; no license/indication text on file) |
| Predicted New Indication | Exposure Keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| India Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, fusidic acid is a fusidane-class antibiotic that inhibits bacterial protein synthesis by blocking elongation factor G (EF-G) translocation, and it is particularly active against Staphylococcus species, including MRSA. Its proven efficacy has historically been in skin, soft-tissue, and ocular surface infections in other markets.
Exposure keratitis, however, is primarily a mechanical/non-infectious corneal disorder caused by inadequate eyelid closure, and only requires antimicrobial therapy when a secondary bacterial infection develops. While fusidic acid ophthalmic formulations do have an antibacterial mechanistic rationale against Staphylococcus, the only literature identified for this pairing is a case series on Tsukamurella species (an atypical actinomycete, not Staphylococcus) causing ophthalmic infection — the mechanistic link between fusidic acid and exposure keratitis specifically remains weak and largely inferred from the drug’s general antistaphylococcal activity rather than direct evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case Series | Cornea | Largest case series of Tsukamurella species-associated ophthalmic infections (including a case of ocular implant infection after enucleation), covering clinical spectrum, risk factors, treatment, and outcome; does not directly evaluate fusidic acid in exposure keratitis. |
India Market Information
Fusidic acid is not currently marketed in India — no product registrations are on file (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (exposure keratitis) has no clinical trials and only one loosely related case series (evidence level L4), and the drug’s own mechanism-of-action data is missing, so there is insufficient basis to advance this specific indication.
To proceed, the following is needed:
- Fusidic acid mechanism of action (MOA) data from DrugBank (DG002)
- TFDA/India package insert warnings and contraindications (DG001, Blocking — required before any safety pre-assessment)
- Original approved indication and license data for fusidic acid (currently absent from regulatory records)
- Preclinical or case-level evidence specifically linking fusidic acid to bacterial keratitis/exposure keratitis with Staphylococcus co-infection
Note on alternative candidates: Within the same evidence pack, two lower-ranked predictions have materially stronger evidence and may warrant separate evaluation — post-bacterial disorder (rank 5, evidence level L2, includes a completed Phase 3 RCT of oral fusidic acid, NCT02570490, recommendation “Proceed with Guardrails”) and otitis externa (rank 3, evidence level L3, supported by 6 publications on staphylococcal otitis pathogens, recommendation “Research Question”). These may represent more actionable repurposing directions than the top-ranked exposure keratitis prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.